Javascript must be enabled to continue!
The Protective Effect of Vitamin D on Dementia Risk in Hemodialysis Patients
View through CrossRef
Background: Patients with end-stage renal disease (ESRD) undergoing hemodialysis are at an elevated risk of developing dementia, potentially linked to the high prevalence of vitamin D deficiency in this population, which may contribute to cognitive impairment. Nevertheless, the impact of vitamin D supplementation on the risk of dementia in hemodialysis patients remains uncertain, necessitating further investigation to elucidate the potential benefits of vitamin D intervention in this vulnerable group. Methods: In this propensity-score-matched comparative cohort study, we sought to assess the impact of vitamin D supplementation on the occurrence of dementia in patients with end-stage renal disease (ESRD) undergoing hemodialysis. A total of 1424 patients were included and matched 1:1 using propensity scores. The study population was divided into two groups: those receiving vitamin D supplementation at a dose of ≥70 μg/week and those without any supplementation. The primary outcome of interest was the incidence of dementia. We calculated adjusted hazard ratios (aHRs) to examine the association between vitamin D supplementation and the risk of dementia while controlling for relevant covariates. Results: The adjusted hazard ratio (aHR) comparing vitamin D supplementation to no supplementation was 0.44 (95% CI 0.29–0.69; p < 0.0001), demonstrating a significant decrease in the risk of dementia associated with vitamin D supplementation. The aHRs for vitamin D supplementation at different dose ranges (70–105, 106–350, 351–1000, and >1000 μg/week) were 0.51, 0.49, 0.43, and 0.41, respectively (p for trend < 0.0001). These findings suggest a potential dose-dependent relationship between vitamin D supplementation and the reduction of dementia risk. Conclusions: In our study, we found that vitamin D supplementation at doses of ≥70 μg/week significantly reduced the risk of dementia in patients with end-stage renal disease (ESRD) undergoing hemodialysis. Furthermore, our results indicated a dose-dependent effect, with higher doses of supplementation correlating with a greater reduction in dementia risk. These findings underscore the potential of vitamin D supplementation as a preventive approach for cognitive impairment in this high-risk population.
Title: The Protective Effect of Vitamin D on Dementia Risk in Hemodialysis Patients
Description:
Background: Patients with end-stage renal disease (ESRD) undergoing hemodialysis are at an elevated risk of developing dementia, potentially linked to the high prevalence of vitamin D deficiency in this population, which may contribute to cognitive impairment.
Nevertheless, the impact of vitamin D supplementation on the risk of dementia in hemodialysis patients remains uncertain, necessitating further investigation to elucidate the potential benefits of vitamin D intervention in this vulnerable group.
Methods: In this propensity-score-matched comparative cohort study, we sought to assess the impact of vitamin D supplementation on the occurrence of dementia in patients with end-stage renal disease (ESRD) undergoing hemodialysis.
A total of 1424 patients were included and matched 1:1 using propensity scores.
The study population was divided into two groups: those receiving vitamin D supplementation at a dose of ≥70 μg/week and those without any supplementation.
The primary outcome of interest was the incidence of dementia.
We calculated adjusted hazard ratios (aHRs) to examine the association between vitamin D supplementation and the risk of dementia while controlling for relevant covariates.
Results: The adjusted hazard ratio (aHR) comparing vitamin D supplementation to no supplementation was 0.
44 (95% CI 0.
29–0.
69; p < 0.
0001), demonstrating a significant decrease in the risk of dementia associated with vitamin D supplementation.
The aHRs for vitamin D supplementation at different dose ranges (70–105, 106–350, 351–1000, and >1000 μg/week) were 0.
51, 0.
49, 0.
43, and 0.
41, respectively (p for trend < 0.
0001).
These findings suggest a potential dose-dependent relationship between vitamin D supplementation and the reduction of dementia risk.
Conclusions: In our study, we found that vitamin D supplementation at doses of ≥70 μg/week significantly reduced the risk of dementia in patients with end-stage renal disease (ESRD) undergoing hemodialysis.
Furthermore, our results indicated a dose-dependent effect, with higher doses of supplementation correlating with a greater reduction in dementia risk.
These findings underscore the potential of vitamin D supplementation as a preventive approach for cognitive impairment in this high-risk population.
Related Results
MBI‐apathy, ApoEɛ2, and risk for Alzheimer disease dementia
MBI‐apathy, ApoEɛ2, and risk for Alzheimer disease dementia
AbstractBackgroundApathy, characterized by decreased interest, initiative, and emotional reactivity, is amongst the most common neuropsychiatric symptoms in dementia. However, apat...
Analysis of the current vitamin A terminology and dietary regulations from vitamin A1 to vitamin A5
Analysis of the current vitamin A terminology and dietary regulations from vitamin A1 to vitamin A5
Abstract: Dietary recommendations on vitamin intake for human food fortification concerning vitamin A in various countries, larger economic zones and international organizations ar...
Effectiveness of vitamin D2 compared with vitamin D3 replacement therapy in a primary healthcare setting: a retrospective cohort study
Effectiveness of vitamin D2 compared with vitamin D3 replacement therapy in a primary healthcare setting: a retrospective cohort study
Introduction: Vitamin D deficiency is a worldwide public health concern, which can lead to severe diseases, such as rickets in children and osteomalacia in adults. Most studies hav...
Walking pace, handgrip strength, age, APOE genotypes, and new-onset dementia: the UK Biobank prospective cohort study
Walking pace, handgrip strength, age, APOE genotypes, and new-onset dementia: the UK Biobank prospective cohort study
Abstract
Background
The independent and additive associations of walking pace and grip strength on dementia risk and the potential modifying effects...
Prescription Patterns of Anti-dementia and Psychotropic Drugs in People Living With Dementia in China
Prescription Patterns of Anti-dementia and Psychotropic Drugs in People Living With Dementia in China
Abstract
Pharmacotherapy of dementia is a critical intervention for managing symptoms of and slowing progression of dementia. However, evidence on prescribing patter...
Comparison of Vitamin A and Vitamin D Levels of 0-36 Months Old Children, Who were Admitted to Pediatric Inpatient Clinic with Lower Respiratory Tract Infection and Healthy Children within the Same Age Group
Comparison of Vitamin A and Vitamin D Levels of 0-36 Months Old Children, Who were Admitted to Pediatric Inpatient Clinic with Lower Respiratory Tract Infection and Healthy Children within the Same Age Group
Background
Lower respiratory system infections are highly common in young children and may require inpatient treatment. Studies have shown that patients treated and followed up fo...
Vitamin D and the Immune System. When? Why? How?
Vitamin D and the Immune System. When? Why? How?
Vitamin D, called “the sunshine vitamin” is essential for the good functioning of the human body. Vitamin D generates its principal effects via the vitamin D receptor (VDR), a spec...
Vitamin D in Critically Ill Patients - From Molecular Damage Interactions to Clinical Outcomes Benefits. When, Why, How?
Vitamin D in Critically Ill Patients - From Molecular Damage Interactions to Clinical Outcomes Benefits. When, Why, How?
Abstract
Vitamin D - „the sunshine vitamin” is essential for the good functioning of the human body. The most important forms of the vitamin D are the vitamin D2 an...

